David N. Lebowitz

Morgan Stanley’s David N. Lebowitz expects Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares to remain range bound, following the announcement by the company that it was discontinuing its Revusiran program. Lebowitz downgraded the rating on the company from Overweight to Equal Weight, while...

Safety and tolerability have been recurrent concerns regarding the drugs produced by Ionis Pharmaceuticals Inc (NASDAQ: IONS), according to Morgan Stanley's David N. Lebowitz, which has kept the stock valuation in check. Lebowitz initiated coverage of the company with an Equal-Weight rating and...